FAS and Hepatic steatosis: Similarly, we noted that of the phenylbenzamides that we tested in vivo all three reduced the hepatic CAIII expression as well as FAS suggesting that CAIII may be a suitable biomarker for measuring the beneficial effects of potential therapeutics on hepatic steatosis in vivo.